Levothyroxine Approval Standards For ANDAs, Brands Should Be Consistent, Jerome Stevens Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Generics should demonstrate same dose consistency as 505(b)(2) applications, the company says. Jerome Stevens requests guidance clarifying ANDA review standards and asks FDA to consider pulling Mylan’s Unithroid generic.